tiprankstipranks
Trending News
More News >
RAPT Therapeutics (RAPT)
NASDAQ:RAPT

RAPT Therapeutics (RAPT) AI Stock Analysis

Compare
364 Followers

Top Page

RA

RAPT Therapeutics

(NASDAQ:RAPT)

Rating:39Underperform
Price Target:
RAPT Therapeutics' overall stock score reflects significant challenges, primarily due to its inability to generate revenue and consistent operational losses. The strong equity position in the balance sheet is a positive, but technical indicators suggest a continued downward trend. The negative valuation metrics further highlight the risks associated with the stock.
Positive Factors
Financial Performance
RAPT reported better than expected net loss per share, which was ($0.08) versus the consensus of ($0.14).
Financial Stability
The company has a solid cash position of approximately $231 million, providing financial stability to support upcoming clinical milestones.
Negative Factors
Market Risks
Risks include negative results from POC studies in China, failure of the U.S. Phase 2b trial of RPT904 in food allergy, and potential failure to secure U.S. approval.
Market Sentiment
RAPT shares are likely to be a sentiment underperformer until RAPT flips its own cards for RPT904.

RAPT Therapeutics (RAPT) vs. SPDR S&P 500 ETF (SPY)

RAPT Therapeutics Business Overview & Revenue Model

Company DescriptionRAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
How the Company Makes MoneyRAPT Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies, as well as government grants and funding for its research initiatives. The company may also license its proprietary technology and intellectual property to other firms, providing another revenue stream. As RAPT advances its product candidates through clinical trials and towards potential commercialization, it anticipates generating revenue from the sale of its therapies upon obtaining necessary regulatory approvals.

RAPT Therapeutics Financial Statement Overview

Summary
RAPT Therapeutics faces significant challenges, primarily due to its inability to generate revenue and consistent operating losses. While the balance sheet shows a strong equity base and low leverage, the company's cash flow and income statement highlight sustainability concerns.
Income Statement
20
Very Negative
RAPT Therapeutics has consistently reported negative net income and EBIT over the past years, indicating ongoing operational challenges. The company has not generated any revenue in recent years, which is a concern for sustainability. The lack of revenue and consistent losses contribute to a low score for the income statement.
Balance Sheet
55
Neutral
The balance sheet shows a relatively strong equity position with a low debt-to-equity ratio, indicating conservative leverage. However, the lack of revenue generation poses a risk to the sustainability of the company's financial health. The equity ratio is high, showing a solid capital structure, but the ongoing losses are a concern.
Cash Flow
30
Negative
The company has consistently reported negative operating and free cash flows, pointing to challenges in generating cash from operations. The reliance on financing activities to support cash flow needs is notable. Despite this, the company has maintained a healthy cash position, mitigating some risk.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.001.53M3.81M5.04M
Gross Profit
-305.00K0.00-3.55M-1.28M2.82M5.04M
EBIT
-122.85M-136.10M-127.06M-85.80M-69.21M-53.21M
EBITDA
-121.71M-126.33M-125.85M-84.75M-68.21M-52.09M
Net Income Common Stockholders
-116.51M-129.87M-116.80M-81.88M-68.21M-52.89M
Balance SheetCash, Cash Equivalents and Short-Term Investments
179.28M231.06M158.86M249.07M189.65M111.51M
Total Assets
187.57M240.32M173.33M266.21M198.64M118.97M
Total Debt
3.83M4.49M6.91M8.99M0.000.00
Net Debt
-56.42M-165.24M-40.57M-29.96M-24.03M-24.92M
Total Liabilities
10.20M50.42M26.29M21.04M12.26M14.79M
Stockholders Equity
177.37M189.90M147.03M245.17M186.38M104.18M
Cash FlowFree Cash Flow
-108.69M-83.42M-98.17M-71.62M-61.78M-40.89M
Operating Cash Flow
-108.63M-83.30M-97.05M-70.77M-61.03M-40.49M
Investing Cash Flow
-20.25M52.70M104.13M-45.49M-81.35M-87.44M
Financing Cash Flow
143.82M152.85M1.45M131.18M141.48M75.46M

RAPT Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.23
Price Trends
50DMA
0.99
Positive
100DMA
1.11
Positive
200DMA
1.45
Negative
Market Momentum
MACD
<0.01
Negative
RSI
66.49
Neutral
STOCH
69.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RAPT, the sentiment is Positive. The current price of 1.23 is above the 20-day moving average (MA) of 0.88, above the 50-day MA of 0.99, and below the 200-day MA of 1.45, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 66.49 is Neutral, neither overbought nor oversold. The STOCH value of 69.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RAPT.

RAPT Therapeutics Risk Analysis

RAPT Therapeutics disclosed 66 risk factors in its most recent earnings report. RAPT Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our current or future product candidates may fail or suffer delays in clinical development that materially and adversely affect their commercial viability. Q4, 2024
2.
Environmental, social and governance matters and any related reporting obligations may impact our business. Q4, 2024
3.
Global trade issues and changes in and uncertainties with respect to trade policies and regulations, including import and export license requirements, trade sanctions, tariffs and international trade disputes, could adversely impact our business and operations and reduce the competitiveness of our products relative to local and global competitors. Q4, 2024

RAPT Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$123.62M-24.73%-1.02%-8.59%
55
Neutral
$241.00M123.38%10.49%47.31%
53
Neutral
$5.14B3.03-44.09%2.83%16.75%-0.06%
51
Neutral
$135.59M87.50-24.22%-23.40%17.80%
39
Underperform
$124.18M-26.10%30.76%
39
Underperform
$162.72M-75.60%-2.29%
$131.14M-515.27%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
RAPT
RAPT Therapeutics
1.23
-2.85
-69.85%
CGEN
Compugen
1.45
-1.07
-42.46%
ADCT
ADC Therapeutics
2.43
-1.14
-31.93%
NKTX
Nkarta
1.75
-4.72
-72.95%
GLSI
Greenwich LifeSciences
9.81
-3.38
-25.63%
SEER
Seer
2.10
0.22
11.70%

RAPT Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
RAPT Therapeutics Announces Board Restructuring in 2025
Neutral
Mar 27, 2025

On March 21, 2025, Dr. Wendye R. Robbins informed RAPT Therapeutics’ Board of Directors that she will not seek re-election at the company’s 2025 annual meeting, marking the end of her tenure. Subsequently, on March 25, 2025, the Board decided to reduce its size from six to five members, effective at the annual meeting.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.